Firmagon Cycle Meet Quiz
Quiz by Vijendar Rajwar
Feel free to use or edit a copy
includes Teacher and Student dashboards
Measure skillsfrom any curriculum
Tag the questions with any skills you have. Your dashboard will track each student's mastery of each skill.
- edit the questions
- save a copy for later
- start a class game
- automatically assign follow-up activities based on students’ scores
- assign as homework
- share a link with colleagues
- print as a bubble sheet
- Q1
What is the impact on PSA-PFS post switching to degarelix fromleuprolide in CS21A trial?
Significant improvement
Numerical decline
Numerical improvement
No impact
30s - Q2
What is the CV events risk reduction with degarelix in Abufarajmeta-analysis?
48%
58%
38%
52%
30s - Q3
What is the impact on overall mortality with degarelix in Abufarajmeta-analysis?
42%
20%
52%
20%
30s - Q4
In which meta-analysis, relugolix was also included to evaluate effect on CV risk?
Abufaraj et al
Cirne et al
Paridaens et al
Ford et al
30s - Q5
Which were the treatment arms in Shao et al, Taiwan RWE study?
GnRH agonists alone
GnRH antagonists alone
GnRH agonists vs GnRH antagonists
GnRH antagonists vs abiraterone
30s - Q6
What is MACE?
Minor Associated CV events
Major Adverse CV events
Minor Adverse CV events
Major Associated CV events
30s - Q7
What MACE risk reduction with GnRH antagonists in Shao et al, Taiwan RW Estudy?
30%
33%
23%
40%
30s - Q8
Which guideline endorses usage of GnRH antagonists in patients with pre-existing CV disease?
EASD
AHA
ESC
ADA
30s - Q9
What was the primary endpoint of CS21 trial?
Suppression of testosterone to ≤ 0.5 ng/mL at 28 day
Suppression of testosterone to ≤ 0.5 ng/mL at all monthly measurements
Suppression of PSA at all monthly measurements
Suppression of PSA at all 28 days
30s - Q10
Which trial provides evidence for effect on LUTS symptoms with degarelix?
CS28
CS35
CS23
CS14
30s - Q11
1. Which factors couldn't influence Degarelix subcutaneous depot formation: (pick all that apply)
Time from reconstitution
Injection velocity
Humidity
Injection depth
30s - Q12
What are the degarelix doses identified as the most effective initiation and maintenance doses in the phase II study CS12?
Initiation dose 200 mg and maintenance doses 80 and 120 mg
Initiation dose 240 mg and maintenance doses 80 and 160 mg
Initiation dose 160 mg and maintenance doses 80 and 160 mg
Initiation dose 240 mg and maintenance doses 80 and 120 mg
30s - Q13
What proportion of patients achieved a median testosterone level ≤0.5ng/mL by Day 3 in the degarelix 80 mg maintenance group in CS21 trial?
99.3%
97.2%
93.5%
96.1%
30s - Q14
Degarelix delayed the time to PSA recurrence or death vs. leuprolide by how long in study CS21A, in patients with baseline PSA >20 ng/mL?
1 month
3 Months
7 Months
6 Months
30s - Q15
As per Albertson et al, what was relative risk reduction of CV events or death at the end of the first year of treatment in men with pre-existing CVD?
56%
66%
36%
76%
30s